Recent Advances in Neuroblastoma
By J. Maris. New England Journal of Medicine, 2010
1,874 citations recorded by the source corpus.
Neuroblastoma, an embryonal cancer of the autonomic nervous system, is the most common cancer diagnosed during the first year of life. Although neuroblastoma accounts for disproportionately high morbidity and mortality among childhood cancers, it has one of the highest rates of spontaneous and complete regression. The author discusses recent advances in our understanding of neuroblastoma.
Subfields: Molecular Biology, Neurology
View Paper: https://www.semanticscholar.org/paper/c452f5d1a9c06f2d7e1f3e3366ca8a690c9e383a
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Molecular Biology
- Russ B. Altman
- Santrupti Nerli
- Nikolaos G. Sgourakis
- Emidio Capriotti
- C. V. Dang
- Andrew C. McShan
- David Haussler
- Chin-Hsien Tai
In Neurology
Citations in the corpus
- MYC on the Path to Cancer (2012, background): “MYC belongs to a family that includesMYCL (L-Myc) andMYCN (N-Myc) (Brodeur et al., 1984; Kohl et al., 1984; Maris, 2010; Nau et al., 1985).”
- CAR T cells targeting tumor-associated exons of glypican 2 regress neuroblastoma in mice (2021, background): “Despite intensified cytotoxic therapy and immunotherapy, outcomes for patients with high-risk NB remain poor, with a long-term survival rate of <50%.(14,15) GPC2 is implied in the regulation of MYCN,(12) which has long been associated with high-risk disease and poor outcome in NB.”
- A Recurrent Mutation in Anaplastic Lymphoma Kinase with Distinct Neoepitope Conformations (2018, background): “High-risk NBL has a survival rate of less than 50% after intensive chemotherapy, radiation therapy, and other approved treatments (11).”
- Glutamine and cancer: cell biology, physiology, and clinical opportunities. (2013, neutral): “MYCN amplification occurs in 20%–25% of neuroblastomas and is correlated with poor outcome (31).”
- A new disease-specific machine learning approach for the prediction of cancer-causing missense variants (2011, background): “Although several advances have been made in cancer therapy [35,36], the disease mechanism is still largely unclear.”